<DOC>
	<DOC>NCT02180724</DOC>
	<brief_summary>This study is evaluating the safety and efficacy of acalabrutinib for the treatment of subjects with Waldenström Macroglobulinemia (WM)</brief_summary>
	<brief_title>An Open-label, Phase 2 Study of Acalabrutinib in Subjects With Waldenström Macroglobulinemia</brief_title>
	<detailed_description />
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>Men and women ≥ 18 years of age A confirmed diagnosis of WM, which requires treatment. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. Agreement to use contraception during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children. A lifethreatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or LVEF &lt; 40% Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or gastric bypass, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. Breast feeding or pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Bruton tyrosine kinase inhibitor</keyword>
	<keyword>Btk</keyword>
	<keyword>Waldenström Macroglobulinemia</keyword>
	<keyword>WM</keyword>
	<keyword>Waldenström</keyword>
	<keyword>Macroglobulinemia</keyword>
</DOC>